The European Commission (EC) has approved Adcetris (brentuximab vedotin) when used alongside chemotherapy as a first treatment for adults with systemic anaplastic large cell lymphoma (sALCL), a type of peripheral T-cell lymphoma (PTCL). The decision to extend Adcetris’ current approval came after the Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), recommended it for this indication in late March. Adcetris can now be given to treatment naive people…
May 19, 2020May 19, 2020